Valuation: Alkermes plc

Market Cap 6.81B 6.08B 5.66B 5.15B 9.72B 659B 9.76B 68.12B 26.69B 336B 25.58B 25.02B 1,079B P/E 2026 *
-78.5x
P/E 2027 * 71.6x
Enterprise Value 7.56B 6.75B 6.28B 5.71B 10.78B 731B 10.83B 75.56B 29.61B 373B 28.38B 27.76B 1,197B EV / Sales 2026 *
4.14x
EV / Sales 2027 * 3.85x
Free-Float
89.45%
Yield 2026 *
-
Yield 2027 * -
1 day-0.14%
1 week-5.03%
Current month+0.22%
1 month-11.39%
3 months-21.71%
6 months+20.33%
Current year+45.14%
1 week 39.1
Extreme 39.105
42.71
1 month 39.1
Extreme 39.105
47.4
Current year 27
Extreme 27
55.67
1 year 27
Extreme 27
55.67
3 years 22.01
Extreme 22.01
55.67
5 years 21.24
Extreme 21.24
55.67
10 years 11.98
Extreme 11.98
71.22
Manager TitleAgeSince
Chief Executive Officer 53 31/07/2026
Director of Finance/CFO 53 14/09/2025
Chief Tech/Sci/R&D Officer 58 29/05/2017
Director TitleAgeSince
Chairman 64 31/08/2011
Director/Board Member 53 31/07/2026
Director/Board Member 74 25/05/2016
Date Insider Type Main position Quantity % Market Cap. Importance
02/10/26 Sell

Compliance Officer

-2,034 0.0012%
03/09/26 Sell

Compliance Officer

-2,034 0.0012%
01/09/26 Exercice

Chief Technology Officer

19,000 0.0113%
Change 5-day change 1-year change 3-year change Capi.($)
-0.15%-5.03%+26.24%+48.37% 6.81B
+0.06%+3.33%+44.15%+93.48% 1,051B
+0.53%+3.86%+37.61%+68.04% 630B
+1.06%+5.08%+21.26%+88.31% 489B
-0.14%+3.91%+69.19%+39.97% 359B
+0.70%+3.21%+24.13%+42.50% 344B
+0.54%+2.73%+14.51%+34.37% 272B
-0.21%+1.80%-5.88%+7.70% 246B
+0.28%+3.15%+42.15%+45.83% 224B
-0.57%+3.84%+27.05%+95.65% 187B
Average +0.22%+2.30%+30.04%+56.42% 381.05B
Weighted average by Cap. +0.31%+2.92%+34.34%+66.41%

Financials

2026 *2027 *
Net sales 1.82B 1.63B 1.51B 1.38B 2.6B 176B 2.61B 18.23B 7.14B 89.97B 6.85B 6.7B 289B 1.94B 1.73B 1.61B 1.47B 2.77B 188B 2.78B 19.42B 7.61B 95.84B 7.29B 7.13B 308B
Net income -90.72M -81.02M -75.37M -68.55M -129M -8.78B -130M -907M -355M -4.48B -341M -333M -14.36B 98.89M 88.32M 82.16M 74.73M 141M 9.57B 142M 989M 387M 4.88B 371M 363M 15.66B
Net Debt 744M 664M 618M 562M 1.06B 72B 1.07B 7.44B 2.91B 36.71B 2.79B 2.73B 118B 670M 598M 557M 506M 956M 64.84B 960M 6.7B 2.62B 33.06B 2.52B 2.46B 106B
Projected Income Statement - Annual - Alkermes plc
Logo Alkermes plc
Alkermes plc is an Ireland-based global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Its pipeline includes late-stage clinical candidates in development for narcolepsy and idiopathic hypersomnia, and orexin 2 receptor agonists in early clinical development for other neurological disorders, including attention-deficit hyperactivity disorder (ADHD) and fatigue associated with multiple sclerosis and Parkinson’s disease. The Company's pipeline includes Olanzapine and samidorphan, Alixorexton, ALKS 4510, ALKS 7290, and Valiloxybate. Its LUMRYZ (sodium oxybate) for extended-release oral suspension is a central nervous system depressant indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients seven years of age and older with narcolepsy.
Employees
2,050
Date Price Change Volume
12/10/26 US$40.63 +0.04% 1,139,624
09/10/26 US$40.61 +1.25% 1,626,971
08/10/26 US$40.11 -3.22% 3,251,030
07/10/26 US$41.45 -0.49% 1,816,098
06/10/26 US$41.65 -2.60% 1,545,961
Trader
Investor
Global
Quality
ESG MSCI
A
Ratings Surperformance© - Alkermes plc
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
19
Last Close Price
40.61USD
Average target price
56.28USD
Spread / Average Target
+38.58%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Alkermes plc
  1. Stock Market
  2. Stocks
  3. ALKS Stock